Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients.

Authors:
Karsten Weller
Karsten Weller
Charité-Universitätsmedizin Berlin
Germany
Charis Papavassilis
Charis Papavassilis
National Taiwan University Hospital and National Taiwan University College of Medicine
Taiwan
Thomas Severin
Thomas Severin
Medical University
Poland
Haijun Tian
Haijun Tian
Albert Einstein College of Medicine
United States
Torsten Zuberbier
Torsten Zuberbier
Charité-Universitätsmedizin Berlin
Germany

Pediatr Allergy Immunol 2018 Apr 21. Epub 2018 Apr 21.

Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Background: Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0-17 years).

Methods: A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country.

Results: Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively. Angioedema was reported in 6%-14% of patients. A large proportion of CSU pediatric patients (40%-60%) were treated with H1-antihistamines at approved dose and 16%-51% received H1-antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1-antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%-28%) and topical creams (15%-26%).

Conclusions: This study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline-recommended alternatives.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pai.12910DOI Listing
April 2018
4 Reads

Publication Analysis

Top Keywords

pediatric patients
20
csu pediatric
16
prevalence csu
12
pediatric population
12
pediatric
10
csu patients
8
diagnosed prevalence
8
topical creams
8
disease management
8
patients
8
prevalence disease
8
pediatric csu
8
chronic spontaneous
8
european countries
8
spontaneous urticaria
8
csu
7
prevalence
7
138% 95%
4
respondents extrapolated
4
95% 094-186
4

Similar Publications

H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.

Clin Exp Allergy 2017 May 2;47(5):684-692. Epub 2017 Mar 2.

Novartis Pharma GmbH, Nürnberg, Germany.

Background: Most data on chronic spontaneous urticaria (CSU) originate from highly selected patient populations treated at specialized centres. Little is known about CSU patient characteristics and the burden of CSU in routine clinical practice. AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is an ongoing global study designed to assess chronic urticaria in the real-life setting. Read More

View Article
May 2017

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria.

Clin Transl Allergy 2015 17;5:29. Epub 2015 Aug 17.

Novartis Pharma AG, Basel, Switzerland.

Background: Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe and distressing skin condition that remains uncontrolled in approximately one half of patients, despite the use of licensed, recommended doses of modern, second-generation H1-antihistamines. So far, the humanistic, societal and economic burden of CSU/CIU has not been well quantified. Therefore it is important to broaden our understanding of how CSU/CIU impacts patients, society, and healthcare systems, by determining the disease burden of CSU/CIU and the associated unmet need; as well as to further guide the use of new treatments in an efficient and cost-effective manner. Read More

View Article
August 2015

Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States.

Dermatol Ther (Heidelb) 2018 Mar 10;8(1):69-83. Epub 2018 Feb 10.

Herbert Wertheim School of Medicine, Florida International University, Miami, FL, USA.

Introduction: Few studies have described chronic idiopathic/spontaneous urticaria (CIU/CSU) healthcare burden in adults, while this information remains largely unknown in children. We aimed to describe treatment patterns, healthcare resource utilization (HRU), and costs in CIU/CSU pediatric patients, as well as to compare HRU and costs in CIU/CSU and CIU/CSU-free pediatric patients.

Methods: Medicaid claims from four states (09/01/2013-03/31/2016) were used to identify patients less than 12 years old. Read More

View Article
March 2018

Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.

Allergy Asthma Proc 2018 May 7;39(3):201-211. Epub 2018 Mar 7.

Herbert Wertheim School of Medicine, Florida International University, Miami, Florida.

Background: Chronic idiopathic urticaria (CIU)/spontaneous urticaria (CSU) is defined by the presence of wheals, angioedema, or both for ≥6 weeks, with or without an identifiable trigger. Real-world health care data among children with CIU/CSU remain scarce.

Objectives: To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (<12 years old) and to compare these with pediatric patients without CIU/CSU. Read More

View Article
May 2018